provider for the most current information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information. boys with steroid-responsive nephrotic syndrome treated with cyclophosphamide for short periods. 2-3 mg/kg/day for up to 12 weeks when corticosteroids unsuccessful . /viewarticle/907414 informational and educational purposes only.
You may hear cyclophosphamide called by its brand names, Cytoxan or Procytox. If you log out, you will be required to enter your username and password the next time you visit. Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. Cyclophosphamide treatment of nephrotic syndrome 1103 treatment with prednisone.
cytoxan-cyclophosphamide-342214 In patients requiring dialysis, use of a consistent interval between administration of this drug and dialysis should be considered.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. This website also contains material copyrighted by 3rd parties. Applies to the following strengths: 100 mg; 200 mg; 500 mg; 1 g; 2 g; 50 mg; 25 mg; lyophilized 100 mg; lyophilized 200 mg; lyophilized 500 mg; lyophilized 1 g; lyophilized 2 gThe doses below can be regarded as general guidelines:The doses below can be regarded as general guidelines:-Mild to moderate renal impairment: No adjustment recommended.-Mild to moderate hepatic impairment: No adjustment recommended.This drug and its metabolites are dialyzable although there are probably quantitative differences depending upon the dialysis system being used. Your list will be saved and can be edited at any time.The above information is provided for general IV (intermittent therapy): 40-50 mg/kg (400-1800 mg/m²) divided over 2-5 days; may be repeated at intervals of 2-4 weeks IV (continuous daily therapy): 60-120 mg/m²/day (1-2.5 mg/kg/day)PO (intermittent therapy): 400-1000 mg/m² divided over 4-5 daysPO (continuous daily therapy): 50-100 mg/m²/day or 1-5 mg/kg/day 2-3 mg/kg/day for up to 12 weeks when corticosteroids unsuccessful 600-1500 mg/m² IV with other antineoplastics (part of CHOP regimen); dose intensification possible 600 mg/m² IV with other antineoplastics; dose intensification possible Induction therapy for lupus nephritis (American College of Rheumatology Guidelines 2012)Low-dose: 500 mg IV every 2 weeks for 6 doses plus corticosteroids, then maintenance with mycophenolate mofetil or azathioprineHigh-dose: 500-1000 mg/m² IV monthly for 6 doses plus corticosteroidsPrevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantHepatic impariment: Give 75% of normal dose if transaminase levels are >3 times upper limit of normal or bilirubin is 3.1-5 mg/dLRenal impairment: CrCl <10 mL/min, give 75% of normal dose; CrCl >10 mL/min, give full dose IV (intermittent therapy): 40-50 mg/kg (400-1800 mg/m²) divided over 2-5 days; may be repeated at intervals of 2-4 weeks IV (continuous daily therapy): 60-120 mg/m²/day (1-2.5 mg/kg/day)PO (intermittent therapy): 400-1000 mg/m² divided over 4-5 days2-3 mg/kg/day for up to 12 weeks when corticosteroids unsuccessful Syndrome of inappropriate antidiuretic hormone secretion (SIADH)Secondary malignancies: Urinary bladder, myeloproliferative, lymphoproliferativeUse with caution in patients with hepatic or renal impairment, leukopenia, thrombocytopenia, recent radiation therapy or chemotherapyPelvic irradiation potentiates hemorrhagic cystitisPotential for radiation recall when used in conjunction with radiation therapyRisk of potentially fatal and irreversible interstitial pulmonary fibrosis if given over prolonged periodsMay cause infertility in male patients who received high doses as childrenBased on mechanism of action and published reports of effects in pregnant patients or animals, drug can cause fetal harm when administered to pregnant woman; exposure to cyclophosphamide during pregnancy may cause fetal malformations, miscarriage, fetal growth retardation, and toxic effects in the newborn; drug is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monkeys; advise pregnant women and females of reproductive potential of the potential risk to the fetusVerify the pregnancy status of females of reproductive potential prior to the initiation of therapyDrug is present in breast milk; neutropenia, thrombocytopenia, low hemoglobin, and diarrhea have been reported in infants breast fed by women treated with cyclophosphamide; because of potential for serious adverse reactions in a breastfed child from therapy, advise lactating women not to breastfeed during treatment and for 1 week after last doseA: Generally acceptable. Diseases & Conditions Cyclophosphamide is a medicine that lowers the body's natural immunity. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvY3l0b3hhbi1jeWNsb3Bob3NwaGFtaWRlLTM0MjIxNA== Nephrotic syndrome is a kidney disorder which causes large amounts of protein to be lost in the urine leading to low levels of protein in the blood. Breast Cancer.